DLDayse Maria Lourenço

Dayse Maria Lourenço

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Research Subjects


Dayse Maria Lourenço has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Recommendations and guidance on Cobalamin (Vitamin B12) based on the Delphi method

    by Tiago Lazzaretti Fernandes, Dayse Maria Lourenço, Durval Ribas Filho, Glaucia Carneiro, Gustavo Loureiro, João Toniolo Neto, Luis Claudio Cameron, Sonia Maria Dozzi Brucki, Nairo Massakazu Sumita, Henry Dan Kiyomoto, et al.

    Introduction: Vitamins are essential micronutrients for the body to function. Cobalamins (Cbls) are watersoluble compounds, acting as cofactors in enzymatic reactions. However, the use of Cbls in the clinical environment is still controversial. Objective: It was to discuss the topic and help guide different professionals, experts were brought together to discuss criteria concerning the diagnosis, indications, and use of cobalamin. Methods: The study was carried out using the Delphi method. Topics were initially created to direct the discussion and initial contributions. In the first meeting with the panelists, questions were formulated. The questions were distributed to all panelists. With the contributions, a text with the answers was created, and a third round to review the contributions and agree with the text was carried out. Results: The main topics related to the use of cobalamin were identified. Conclusion: The main topics related to this topic include risk groups of deficiency of ingestion or absorption by the gastrointestinal tract. The deficiency diagnosis must be made through laboratory tests, and early indication must be made when a significant cobalamin deficiency is identified, to avoid irreversible clinical conditions. A recommended practice is monitoring between 2 and 6 months after starting cobalamin replacement. Evidence Level:6.